![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Week 48 results of the randomised, multicentre Maraviroc Switch study
(MARCH)
|
|
|
Reported by Jules Levin
EACS 2015 Oct 21-24 Barcelona, Spain - 15th European AIDS Conference
Sarah L. Pett1,2,3 on Behalf of the MARCH study group
1Kirby Institute, University of New South Wales, Sydney, Australia; 2MRC CTU at UCL, Institute of Clinical Trials and Methodology, and 3Clinical Research Group, Infection and Population Health, UCL, London, UK
![EACS1.gif](../images/102815/102815-4/EACS1.gif)
![EACS2.gif](../images/102815/102815-4/EACS2.gif)
![EACS3.gif](../images/102815/102815-4/EACS3.gif)
![EACS4.gif](../images/102815/102815-4/EACS4.gif)
![EACS5.gif](../images/102815/102815-4/EACS5.gif)
![EACS6.gif](../images/102815/102815-4/EACS6.gif)
![EACS7.gif](../images/102815/102815-4/EACS7.gif)
![EACS8.gif](../images/102815/102815-4/EACS8.gif)
![EACS9.gif](../images/102815/102815-4/EACS9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|